Montana Adolescent Immunization Coverage Rates Ages 13–17

How Montana Compared to the US Rates in 2017

- Tdap
- Varicella
- Meningococcal ACWY
- >1 HPV Females
- >1 HPV Males
- HPV Up to Date Females
- HPV Up to Date Males

CDC Recommends

HPV Vaccine

for all preteen boys and girls to protect against cancers caused by HPV

MT Higher than US Average

HPV Up to Date Males

Montana 48.1%

US 44.3%

MT Lower than US Average

HPV Up to Date Females

Montana 50.1%

US 53.1%

Meningococcal Conjugate

Montana 71.2%

US 85.1%

≥1 Tdap: ≥1 dose of tetanus, diphtheria, acellular, pertussis vaccine at or after age 10 years; ≥2 doses of varicella vaccine if no history of disease; ≥1 MenACWY: ≥1 dose of quadrivalent meningococcal conjugate vaccine; ≥1 HPV: ≥1 dose of human papillomavirus vaccine; HPV Up to date: includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated at age <15 years and at least five months minus four days elapsed between the first and second dose as specified by Clinical Decision Support for Immunization (CDSi). This update to the HPV recommendation occurred in December of 2016.


0 50 100

% Vaccinated

2013 2014 2015 2016 2017

≥1 Tdap: ≥1 dose of tetanus, diphtheria, acellular, pertussis vaccine at or after age 10 years; ≥2 doses of varicella vaccine if no history of disease; ≥1 MenACWY: ≥1 dose of quadrivalent meningococcal conjugate vaccine; ≥1 HPV: ≥1 dose of human papillomavirus vaccine; HPV Up to date: includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated at age <15 years and at least five months minus four days elapsed between the first and second dose as specified by Clinical Decision Support for Immunization (CDSi). This update to the HPV recommendation occurred in December of 2016.